특발성 황반원공에서 유리체 단백질 발현에 관한 분석
Human Vitreous Proteomes in Idiopathic Macular Hole
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 황반원공의 유리체 단백질 발현양상을 정상안 및 황반전막과 비교하여 그 차이를 알아보았다. 대상과 방법: 정상안 10안, 유리체황반견인증후군 4안, 황반원공 25안(후유리체박리가 없는 15안과 있는 10안), 후유리체박리가 있는황반전막 10안에서 유리체를 얻어 micro-RPLC-MS/MS 기법으로 단백질을 정성적으로 분석하였다. 확인된 단백질의 기능적 분류,조직에서 위치 및 조직 특이성을 조사하였다. 결과: 총 단백질 농도는 후유리체박리가 없는 황반원공에서 가장 높았다(p＜0.01). 정상안에서 나이에 따른 유리체 단백질 발현의 차이는 발견되지 않았지만 보고된 적 없는 12개(vasorin 등)의 새로운 단백질을 정상안 유리체에서 발견하였다. 총 136개 단백질 중 10개(retinoschisin 등, 7.3%)가 황반원공에서만 특이적으로 발현되었다. 후유리체박리가 없는 안에서 특이적으로 발현된 단백질은 S100A8등 6개였고 후유리체박리가 있는 안에서 특이적으로 발현되는 단백질은 CD59 등 6개였다. 결론: 황반원공의 유리체 단백질 발현은 정상안과 황반전막과 비교하여 미세한 차이가 있었고 후유리체박리 유무와 유의한 관련이있었다.
Abstract
Purpose: To investigate the vitreous proteomic profiles of macular hole (MH) patients compared to donor eyes and epiretinal membrane (ERM) patients. Methods: Ten donor eyes, 25 MH patients (15 MH without posterior vitreous detachment (PVD) and 10 MH with PVD), 10ERM patients and 4 patients with vitreomacular traction syndrome (VMTS) were enrolled in the present study. The undiluted vitreous samples were obtained from all eyes. Proteins were identified using the micro-RPLC/MS/MS technique and using mass spectrometric data analysis from the IPI database. Proteins were searched for the function, subcellular location and tissue specificity using the Uniprot database. Results: The mean vitreous protein concentrations were the highest (p < 0.01) in MH patients without PVD. There were no qualitative changes according to the age of donor eyes. However, the authors newly-identified 12 proteins (i.e. vasorin) in donor eyes. Ten out of 136 proteins (7.3%) (i.e. retinoschisin) were exclusively detected in the MH samples. S100A8 was exclusively detected in eyes without PVD, whereas CD59 was exclusively detected in eyes with PVD. Conclusions: The results suggest there is a small difference in the vitreous proteomic profiles in MH patients compared to donor eyes or ERM patients, and that the expression of vitreous proteins is closely associated with the presence of PVD.
참고문헌 (40)
- Sebag J, "Morphology and ultrastructure of human vitreous fibers", Invest Ophthalmol Vis Sci, 30, pp.1867~1871 (1989)
- Lazarus HS, "In situ characterization of the human hyalocyte", Arch Ophthalmol, 112, pp.1356~1362 (1994)
- Gärtner J, "The fine structure of the vitreous base of the human eye and pathogenesis of pars planitis", Am J Ophthalmol, 71, pp.1317~1327 (1971)
- Bishop PN., "Structural macromolecules and supramolecular organisation of the vitreous gel", Prog Retin Eye Res, 19, pp.323~344 (2000)
- Gaudric A, "Macular hole formation: new data provided by optical coherence tomography", Arch Ophthalmol, 117, pp.744~751 (1999)
- Hikichi T, "Course of vitreomacular traction syndrome", Am J Ophthalmol, 119, pp.55~61 (1995)
- Foos RY., "Ultrastructural features of posterior vitreous detachment", Albrecht Von Graefes Arch Klin Exp Ophthalmol, 196, pp.103~111 (1975)
- Yamane K, "Proteome analysis of human vitreous proteins", Mol Cell Proteomics, 2, pp.1177~1187 (2003)
- Peng J, "Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC", LC-MS, J Proteome Res, pp.2003, 2[DOI]
- Shen Y, "High-efficiency nanoscale liquid chromatography coupled on-line with mass spectrometry using nanoelectrospray ionization for proteomics", Anal Chem, 74, pp.4235~4249 (2002)
- Gao BB, "Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy", J Proteome Res, 7, pp.2516~2525 (2008)
- Kim T, "Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients", Proteomics, 7(22), pp.4203~4215, John Wiley & Sons Ltd.
- Yu J, "Vitreous proteomic analysis of proliferative vitreoretinopathy", Proteomics, 8, pp.3667~3678 (2008)
- Lim SY, "Oxidative modifications of S100 proteins: functional regulation by redox", J Leukoc Biol, 86, pp.577~587 (2009)
- Marenholz I, "S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature)", Biochem Biophys Res Commun, 322, pp.1111~1122 (2004)
- Ehrchen JM, "The endogenous Toll-like receptor 4 agonist S100A8", S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer, 2009, pp.86, 557~566
- Lavrovsky Y, "Role of redox- regulated transcription factors in inflammation, aging and age-related diseases", Exp Gerontol, 35, pp.521~532 (2000)
- Qiao H, "The characterisation of hyalocytes: the origin, phenotype, and turnover", Br J Ophthalmol, 89, pp.513~517 (2005)
- Kita T, "Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target", Proc Natl Acad Sci U S A, 105, pp.17504~17509 (2008)
- Kohno RI, "Possible contribution of hyalocytes to idiopathic epiretinal membrane formation and its contraction", Br J Ophthalmol, 93, pp.1020~1026 (2009)
- Sommer F, "Hyalocyte proliferation and ECM accumulation modulated by bFGF and TGF-beta1", Graefes Arch Clin Exp Ophthalmol, 246, pp.1275~1284 (2008)
- Hata Y, "Role of tumour necrosis factor-α(TNFα) in the functional properties of hyalocytes", Br J Ophthalmol, 95, pp.261~265 (2011)
- Gandorfer A, "Pathology of the macular hole rim in flat-mounted internal limiting membrane specimens", Retina, 29, pp.1097~1105 (2009)
- Molday RS, "Focus on molecules: retinoschisin (RS1)", Exp Eye Res, 84, pp.227~228 (2007)
- Karlstetter M, "The novel activated microglia", macrophage WAP domain protein, AMWAP, acts as a counter-regulator of proinflammatory response, 2010, pp.185, 3379~3390
- Bonilha VL, "Characterization of semenogelin proteins in the human retina", Exp Eye Res, 83, pp.120~127 (2006)
- Lazarus HS, "Hyalocytes synthesize and secrete inhibitors of retinal pigment epithelial cell proliferation in vitro", Arch Ophthalmol, 114, pp.731~736 (1996)
- Schönfeld CL, "Hyalocytes inhibit retinal pigment epithelium cell proliferation in vitro", Ger J Ophthalmol, 5, pp.224~228 (1996)
- Doshi BM, "HSPB1, actin filament dynamics, and aging cells", Ann N Y Acad Sci, 1197, pp.76~84 (2010)
- Miki H, "Regulation of actin dynamics by WASP family proteins", J Biochem, 134, pp.309~313 (2003)
- Yang P, "Expression and modulation of RPE cell membrane complement regulatory proteins", Invest Ophthalmol Vis Sci, 50, pp.3473~3481 (2009)
- Vogt SD, "Distribution of complement anaphylatoxin receptors and membrane-bound regulators in normal human retina", Exp Eye Res, 83, pp.834~840 (2006)
- Liversidge J, "CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2-mediated alternative pathway of T cell activation", J Immunol, 156, pp.3696~3703 (1996)
- Fatma N, "Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca2+ homeostasis", Brain Res, 1233, pp.63~78 (2008)
- Henderson NC, "The regulation of inflammation by galectin-3", Immunol Rev, 230, pp.160~171 (2009)
- Scott IC, "Mammalian BMP-1", Tolloid-related metalloproteinases, including novel family member mammalian Tolloid-like 2, have differential enzymatic activities and distributions of expression relevant to patterning and skeletogenesis, 1999, pp.213, 283~300
- Saika S, "Fibrotic disorders in the eye: targets of gene therapy", Prog Retin Eye Res, 27, pp.177~196 (2008)
- Wang KC, "Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth", Nature, 417, pp.941~944 (2002)
- Shukunami C, "Chondromodulin-I and tenomodulin: a new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues", Biochem Biophys Res Commun, 333, pp.299~307 (2005)
- Ikeda Y, "Vasorin, a transforming growth factor beta-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo", Proc Natl Acad Sci U S A, 101, pp.10732~10737 (2004)